TSND-201 (methylone) demonstrated a statistically significant reduction in CAPS-5 total severity scores compared to placebo at day 64 (p = .01).
Significant improvements were observed across secondary endpoints, including the PTSD Checklist for DSM-5 (PCL-5), Sheehan Disability Scale (SDS), and Montgomery-Åsberg Depression Rating Scale (MADRS).
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.